Recent Press Releases
CALGARY, Alberta, Jan. 28, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (PKD), is pleased to announce that Dr.
Recent Press Releases
CALGARY, Alberta, Nov. 26, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (PKD), is pleased to announce that the Company along with its collaborative partner, Cato Clinical Research, has received a response letter from the US Food and Drug Administration (FDA) regarding the recent Orphan Drug Designation (ODD) application for XORTX’s XRx-008 program for the treatment of autosomal dominant polycystic kidney disease ( ADPKD).
Recent Press Releases
CALGARY, Alberta, Nov. 06, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (“PKD”), is pleased to announce the appointment of James Fairbairn as Chief Financial Officer.
Recent Press Releases
● Shorter Path to XRx-008 Marketing Approval ●
CALGARY, Alberta, Oct. 23, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (“PKD”), is pleased to announce that the Company’s clinical development plan has been reviewed and accelerated.
Recent Press Releases
CALGARY, Alberta, Oct. 15, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of two new members to the Company’s clinical advisory board, Dr.
Recent Press Releases
CALGARY, Alberta, Sept. 10, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company along with its collaborative partner, Cato Clinical Research, has submitted documents to the US Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) status for XORTX’s XRx-008 (a proprietary formulation of Oxypurinol) program for the treatment of autosomal dominant polycystic kidney disease ( ADPKD).
Recent Press Releases
● Advancing to a Phase II Clinical Study in Polycystic Kidney Disease ●
CALGARY, Alberta, Aug. 13, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company with its collaborative partner, Cato Clinical Research, has filed its pre-IND meeting documents with the FDA.
Recent Press Releases
CALGARY, Alberta, June 28, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide the results of the Company’s annual and special meeting of shareholders and to provide a corporate update and summary of activities since the close of the reverse takeover (RTO), CSE listing and private placement in January 2018, where XORTX has advanced a number of key initiatives towards its goal to advance its two leading development programs into clinical phase II studies.
› Read more
Recent Press Releases
CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company along with Cato Clinical Research has filed its pre-IND meeting request letter with the FDA.
Recent Press Releases
CALGARY, Alberta, June 06, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company’s shares have been approved to commence trading on the OTCQB Venture Market under the symbol XRTXF effective June 7, 2018.